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Conclusion: We have developed a novel method to simulate a 
model based virtual RS that is a useful tool to identify 
patients with a potentially high benefit of a RS implantation. 
The volume of the virtual RS can be estimated through the 
use of different deformation fields. In future, a dose 
comparison study is necessary to extend into a full decision 
support system using the virtual RS approach. 
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Purpose or Objective: The escalation dose in the treatment 
of prostate cancer with external beam radiation therapy has 
proved the winning way in the biochemical control of the 
tumor. But the dose escalation to the whole prostate gland, 
which is considered as clinical target volume in external 
beam radiotherapy, is limited by the tolerance of the 
surrounding tissue. We have compared the toxicity profiles 
between patients treated with moderate hypofractionated 3-
dimensional conformal radiotherapy (3D-CRT) collated with 
volumetric-modulated arc therapy (VMAT), both with image-
guided radiotherapy (IGRT) by implanted fiducial markers in 
prostate gland (FMs) . 
 
Material and Methods: Between 2009 and 2011, 41 patients 
with prostate cancer were treated with 3DCRT-IG to a dose 
of 70 Gy 2.5 Gy/fr with daily online correction of the target 
position based on MV/MV. This group of patients was 
compared with a similar cohort of 39 patients who were 
treated between 2012 and 2014 with VMAT-IG to the same 
prescription dose with daily online correction of the target 
position based on MV/KV imaging. The clinical characteristics 
of these two patient populations are shown in Table 1. 
Radiation Therapy Oncology Group/European Organization for 
Research and Treatment of Cancer late morbidity 
RTOG/EORTC scores were used for acute and late effects. 
The median follow-up time was 3 years (range, 1-6 years). 
The rectal and bladder dose parameters were also included in 
the statistical analysis. 
 
 
 
Results: The rectal acute and late toxicity was low for both 
treatment groups and no significant reduction was observed 
for VMAT-IG patients compared with the 3DCRT-IG patients (P 
= 0.33). The likelihood acute genitourinary toxicity for the 
VMAT-IG and 3DCRT-IG cohorts were 14.5% and 18.0%, 
respectively (p = 0.61). Only for grade ≥ 2 acute 
genitourinary toxicity, the analyses showed a trend better 
but non significative result on behalf of VMAT-IG (P=0,09). 
Finally, no significant correlation was observed between the 
dose parameters and genito-urinary and rectal late toxicity 
The PSA relapse-free survival in according to Phoenix criteria 
(nadir plus 2 ng/ml) for 3D-CRT and VMAT were similar (98% 
vs. 96%; p = 0.34). 
 
Conclusion: Moderate hypofractionated IGRT is associated 
with a lower rate of genito-urinary and rectal toxicity for 
both treatment 3D-CRT and VMAT. These data suggest that, 
the placement of fiducial markers and daily online correction 
of target positioning may represent the preferred mode of 
external-beam radiotherapy delivery for the patients treated 
by definitive radiotherapy. 
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Purpose or Objective: To evaluate the outcome of 
stereotactic body Vero® linac- or Cyberknife®-based 
radiotherapy (SBRT) for oligometastatic lymph node recurrent 
prostate cancer. 
 
Material and Methods: Between 05/2012 and 09/2015 117 
patients were treated (180 lymph nodes). Median age, initial 
PSA (iPSA), pre-SRT PSA and Gleason score (GS) were 70.3 
years, 10.3 ng/mL, 4.4 ng/mL and 7, respectively. Any 
previous treatment was allowed. In all but 4 patients, 
[11C]choline-positron emission tomography/computer 
tomography was performed. SBRT consisted in re-irradiation 
and first radiotherapy for 29 (16%) and 151 (84%) lesions, 
respectively. Median dose was 24 Gy/3 fractions. Cyberknife-
SBRT or Vero linac-SBRT was applied in 20 (11%) and 160 
(89%) lymph nodes, respectively. In 56 (48%) patients 
androgen deprivation was added to SBRT (median duration 
13.9 months), some patients were heavily pre-treated and 
castration-resistant. Biochemical failure was defined as post-
SBRT PSA increase over pre-SBRT value. Toxicity was 
evaluated using Radiation Therapy Oncology Group/European 
Organization for Research and Treatment of Cancer 
(RTOG/EORTC) criteria. 
 
Results: All patients completed planned SBRT. The median 
follow-up was 19.7 months. Acute toxicity included urinary (7 
G1 events) and rectal complications (2 G1 events). Late 
toxicity included only urinary complications (2, 2, and 2 G1, 
G2, and G4 events, respectively). Both G4 events were 
temporary and were observed in pts receiving re-RT, with no 
dose to bladder from SBRT. Complete or partial biochemical 
response was observed in 68(68%) out of 100 evaluable 
patients. PSA stabilization was seen for 7(7%) patients and in 
24(24%) cases PSA progression was reported. Clinical 
progression during follow up was observed in 65(65%) patients 
after a median time of 9 months (range: 1 – 33.1 months) 
from SBRT. In-field progression was observed in 13(13%) 
cases. 31(31%) patients had distant metastases and 34(34%) 
showed regional lymph node progression. All events of 
clinical failure were preceded by biochemical progression. At 
the time of the analysis (October 2015), 17(14.5%) patients 
are alive with no evidence of disease, 79(67.5%) are alive 
with clinically evident disease, 4(3.5%) died of disease and 
17(14.5%) are not evaluable (due to short follow-up). 
 
Conclusion: Our series including 117 unselected pts showed 
that Vero Linac- or Cyberknife-based SBRT is feasible for 
oligometastatic lymph node recurrent prostate cancer 
offering excellent in-field tumor control and low toxicity 
profile. Further investigation is warranted in order to identify 
the patients that benefit most from this treatment modality. 
The optimal combination with androgen deprivation or other 
systemic treatments should also be defined. 
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Purpose or Objective: The aim of our retrospective study 
was to analyze the role of [(11)C]choline-Positron Emission 
Tomography/Computed Tomography (cho-PET/CT) in the 
management of patients (pts) with biochemical failure after 
curative surgery in patients with prostate cancer. 
 
Material and Methods: We reviewed all patients referred to 
our department with biochemical failure and without 
evidence of recurrence on standard imaging (pelvic MRI + 
total body CT-scan) after curative surgery for prostate 
cancer. All patients underwent cho-PET/CT scans between 
2010 and 2014.  
 
Results: Thirty-four patients fulfilled the inclusion criteria 
and were included in this study. Previous surgical procedure 
was: radical prostatectomy (19 pts), radical prostatectomy 
with pelvic lymph node dissection (8 pts) and radical 
prostatectomy with lymph node sampling (9 pts). Thirty-six 
scan cho-PET/CT studies were performed on 34 patients. 
Median PSA level before cho-PET/CT was 1.7 ng/mL (range 
0.2 to 7.6). Cho-PET/CT showed 21 uptakes in prostate bed, 
4 in prostate bed and pelvic lymph nodes, 1 in prostate bed 
and paraaortic lymph nodes, 5 in pelvic lymph nodes, 1 in 
retroperitoneal lymph nodes (4 exams were negative). Eleven 
pts underwent salvage radiotherapy, 21 pts salvage 
radiotherapy and androgen deprivation therapy and 1 patient 
androgen deprivation therapy only. With a median follow-up 
of 15 months, 27 showed complete biochemical response to 
salvage therapy (PSA <0.04 ng\ml), and are still free from 
biochemical recurrence. Two pts showed biochemical failure, 
3 developed lymph node recurrence and 2 patients developed 
bone metastases.  
 
Conclusion: Cho-PET/CT was able to detect macroscopic 
disease in prostate cancer pts with biochemical failure after 
surgery allowing individualized salvage treatment. 
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Purpose or Objective: To retrospectively evaluate external 
beam re-irradiation (re-EBRT) delivered to either the 
prostate or prostatic bed for local recurrence after radical or 
adjuvant/salvage radiotherapy. 
 
Material and Methods: Between February 2008 and March 
2015, 59 patients received re-EBRT. Median age was 63.8 
years (range 47.1-81.7) and median PSA at the time of 
relapse was 20.2 ng/ml (range 4.4-110). All patients had 
clinical and/or radiological local relapse in the prostate or 
prostatic bed and no distant metastasis at the time of re-
EBRT. A concomitant hormonal treatment was administered 
to 18 patients. Re-EBRT was delivered with image-guided 
stereotactic technology including Rapid Arc®, VERO® and 
Cyberknife® to a total dose of 15-32 Gy in 3-6 fractions. 
Toxicity was evaluated using RTOG/EORTC Criteria. 
Biochemical control was assessed according to Phoenix 
definition. 
 
Results: Only one patient experienced an acute GI event 
>G3, while two patients had late ≥G3 urinary toxicity.  
At a mean and median follow-up of 24.1 and 19.8 months 
respectively (range 2-65.5), 27 patients (45%) show no 
evidence of disease, 26 (44%) are alive with biochemical or 
clinical disease and 2 have been lost at clinical follow-up. 4 
